IL1B and neoplasm: It inhibits the activation of inflammasomes mediated by NF-κB, TNF-α and mitochondrial autophagy, resulting in reduced secretion of IL-1β and IL-6, thereby delaying the progression of colon cancer and reducing the tumor load (67, 110).